基于性别与合并症确定巴雷特食管内镜监测停止年龄的成本效果分析
该研究用3个独立模型模拟无异常增生巴雷特食管(NDBE)患者,按年龄、性别和合并症水平分层,计算当前年龄增加1次内镜监测的增量成本效果比。以10万美元/QALY为支付意愿阈值,确定最佳停止监测年龄。结果显示男性无、轻、中、重度合并症的最佳末次监测年龄分别为81、80、77、73岁,女性更早,分别为75、73、73、69岁。
要点
- NDBE监测获益随年龄、性别和合并症水平变化显著。
- 男性重度合并症最佳停止监测年龄为73岁,女性为69岁。
- 决策停止监测年龄时应考虑合并症状态和性别。
核心结论
- 比较模型分析表明,决定NDBE患者停止监测年龄时,合并症状态和性别均须纳入考虑。
研究设计与样本
- 使用3个独立开发模型模拟诊断为NDBE的患者,按年龄、性别和合并症水平(无、轻、中、重度)分层。
- 所有患者均定期监测至当前年龄,计算当前年龄增加1次内镜监测与不监测的增量成本和QALY。
- 以增量成本效果比刚好低于10万美元/QALY支付意愿阈值的年龄定义为最佳停止监测年龄。
主要发现
- 男性无、轻、中、重度合并症的最佳末次监测年龄分别为81、80、77、73岁。
- 女性无、轻、中、重度合并症的最佳末次监测年龄分别为75、73、73、69岁。
关键数值与推荐
- 支付意愿阈值为10万美元/QALY。
- 男性无合并症最佳末次监测年龄81岁,轻度80岁,中度77岁,重度73岁。
- 女性无合并症最佳末次监测年龄75岁,轻度73岁,中度73岁,重度69岁。
临床怎么用
- 临床决定NDBE患者停止内镜监测时,应结合性别和合并症水平个体化评估。
- 重度合并症女性可考虑在69岁左右停止监测,重度合并症男性可考虑在73岁左右停止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Current guidelines recommend surveillance for patients with nondysplastic Barrett's esophagus (NDBE) but do not include a recommended age for discontinuing surveillance. This study aimed to determine the optimal age for last surveillance of NDBE patients stratified by sex and level of comorbidity. METHODS: We used 3 independently developed models to simulate patients diagnosed with NDBE, varying in age, sex, and comorbidity level (no, mild, moderate, and severe). All patients had received regular surveillance until their current age. We calculated incremental costs and quality-adjusted life-years (QALYs) gained from 1 additional endoscopic surveillance at the current age versus not performing surveillance at that age. We determined the optimal age to end surveillance as the age at which incremental cost-effectiveness ratio of 1 more surveillance was just less than the willingness-to-pay threshold of $100,000/QALY. RESULTS: The benefit of having 1 more surveillance endoscopy strongly depended on age, sex, and comorbidity. For men with NDBE and severe comorbidity, 1 additional surveillance at age 80 years provided 4 more QALYs per 1000 patients with BE at an additional cost of $1.2 million, whereas for women with severe comorbidity the benefit at that age was 7 QALYs at a cost of $1.3 million. For men with no, mild, moderate, and severe comorbidity, the optimal ages of last surveillance were 81, 80, 77, and 73 years, respectively. For women, these ages were younger: 75, 73, 73, and 69 years, respectively. CONCLUSIONS: Our comparative modeling analysis illustrates the importance of considering comorbidity status and sex when deciding on the age to discontinue surveillance in patients with NDBE.
引用
- Omidvari AH, Hazelton WD, Lauren BN, et al. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology. 2021. PMID: 33974935. doi:10.1053/j.gastro.2021.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。